Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450052 | 0.75 | GBA1 (0.42) | CALM1GBA1 | |
| SCHEMBL10952260 | 0.73 | TP53 (0.39) | CALM1GBA1TP53 | |
| SCHEMBL3090521 | 0.72 | FAAH (0.50) | GBA1 | |
| SCHEMBL17867428 | 0.69 | NOS1 (0.35) | GBA1TSHRTP53ALDH1A1TRPA1 | |
| SCHEMBL4357593 | 0.67 | CALM1 (0.45) | CALM1GBA1TSHRTP53ALDH1A1 | |
| SCHEMBL6916462 | 0.67 | GBA1 (0.43) | CALM1GBA1 | |
| SCHEMBL7812033 | 0.67 | GBA1 (0.54) | GBA1ALDH1A1MAPTHTT | |
| SCHEMBL19951526 | 0.65 | LTB4R (0.44) | GBA1TSHRALDH1A1TRPA1 | |
| SCHEMBL22206478 | 0.65 | GBA1 (0.44) | GBA1TSHRALDH1A1TRPA1 | |
| SCHEMBL2027845 | 0.65 | GBA1 (0.71) | GBA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | claimed |
| EP-1768986-A2 | FURANOPYRIMIDINES | Amgen Inc. (US) | 2007-04-04 | — | — | EP | claimed |
| US-20060040961-A1 | Furanopyrimidines | AMGEN INC. | 2006-02-23 | — | — | US | claimed |
| WO-2006004658-A2 | FURANOPYRIMIDINES | AMGEN INC. (US) | 2006-01-12 | — | — | WO | claimed |
| EP-1801189-B1 | Synergistic lubricating oil composition containing a mixture of a benzo[b]perhydroheterocyclic arylamine and a diarylamine | CHEVRON ORONITE CO (US) | 2012-11-07 | — | — | EP | disclosed |
| US-8003583-B2 | Benzo[b]perhydroheterocyclic arylamines and lubricating oil compositions | CHEVRON ORONITE COMPANY LLC (US) | 2011-08-23 | — | — | US | disclosed |
| US-7776867-B2 | Furanopyrimidines | AMGEN INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7501386-B2 | Lubricants for automotive and truck crankcase lubricants; as well as transmission lubricants, gear lubricants, hydraulic fluids, compressor oils, diesel and marine lubricants; superior oxidation inhibition; Phenyl-(1,2,3,4-tetrahydro-quinolin-6-yl)-amine, diphenylamine | CHEVRON ORONITE COMPANY, LLC (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1801104-A2 | Benzo[b]perhydroheterocyclic arylamines and lubricating oil compositions | Chevron Oronite Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1801189-A2 | Synergistic lubricating oil composition containing a mixture of a benzo[b]perhydroheterocyclic arylamine and a diarylamine | Chevron Oronite Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20070142243-A1 | Synergistic lubricating oil composition containing a mixture of a benzo[b]perhydroheterocyclic arylamine and a diarylamine | CHEVRON ORONITE COMPANY LLC | 2007-06-21 | — | — | US | disclosed |
| US-20070142246-A1 | Benzo[b]perhydroheterocyclic arylamines and lubricating oil compositions | CHEVRON ORONITE COMPANY LLC | 2007-06-21 | — | — | US | disclosed |
| EP-1263065-B1 | Use of crosslinkable silicone rubbers, stable against degradation as sealants in fuel cells | WACKER CHEMIE GMBH (DE) | 2004-08-04 | — | — | EP | disclosed |
| EP-1263065-A1 | Use of crosslinkable silicone rubbers, stable against degradation as sealants in fuel cells | Wacker-Chemie GmbH (DE) | 2002-12-04 | — | — | EP | disclosed |
| EP-0902056-B1 | Compressible sulphur containing silicon rubber | WACKER CHEMIE GMBH (DE) | 2002-09-25 | — | — | EP | disclosed |
| EP-0834534-B1 | Liquid silicone rubber composition with reduced compression set | WACKER CHEMIE GMBH (DE) | 2001-11-07 | — | — | EP | disclosed |
| EP-0940446-B1 | RTV-2 silicone foams having low compression set | WACKER CHEMIE GMBH (DE) | 2001-03-07 | — | — | EP | disclosed |
| EP-0940446-A1 | RTV-2 silicone foams having low compression set | WACKER-CHEMIE GMBH (DE) | 1999-09-08 | — | — | EP | disclosed |
| EP-0902056-A2 | Compressible sulphur containing silicon rubber | Wacker-Chemie GmbH (DE) | 1999-03-17 | — | — | EP | disclosed |
| EP-0834534-A1 | Liquid silicone rubber composition with reduced compression set | Wacker-Chemie GmbH (DE) | 1998-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040961-A1 | Furanopyrimidines | TYMS, IDO1, NFATC1 | CALM1 2789/4885GBA1 2625/4885TSHR 126/4885 |
| US-20070142246-A1 | Benzo[b]perhydroheterocyclic arylamines and lubricating oil compositions | AHR, ARNT, HRH2 | CALM1 3151/4885GBA1 1305/4885TSHR 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.